Chugai Renews its Website for the First Time in Six Years
Refurbishing its design and site structure and improving accessibility and usability

January 12, 2010 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo, President: Osamu Nagayama (hereafter, “Chugai”) ] renewed its website on January 7, 2010 to provide corporate information as well as the latest, useful information on diseases and drugs to more stakeholders. This is the first renewal in six years since December 2003.

In this renewal, we not only refurbished the site’s design and structure but also improved accessibility and operability as well as usability such as an information retrieval function which enables users to easily reach their targeted information. Major points of renewal are as follows.

[Points of Renewal]

(1) Improvement of accessibility
We built the following three websites divided by topic in order to rearrange the posted information and enable users to quickly reach their targeted information by reducing the number of layers.
◇ “Corporate information site” http://www.chugai-pharm.co.jp/
   It provides corporate information, news releases, CSR information, information for shareholders and investors, information on employment opportunities, etc.
◇ “Disease and drug site” http://chugai-pharm.info/ (Japanese only)
   It provides information on diseases and drugs and introduces activities initiated by Chugai for all people including patients and their family members.
◇ “Healthcare professional site” http://chugai-pharm.jp/ (Japanese only)
   (to be renewed in May 2010)
   It provides information on proper use of drugs marketed by Chugai exclusively for healthcare professionals.

(2) Improvement of usability
We pursued usability for all users by enhancing the guide and retrieval functions.

In the “Corporate information site” by adopting a new design of the corporate ad on the main visual site, we clearly make the case that Chugai provides useful drugs that are important to society.

As a top pharmaceutical company of biopharmaceuticals and antibody drugs, Chugai will continue to deliver up-to-date, useful information to everyone through this website.
About Chugai

Chugai Pharmaceutical, one of Japan’s leading research-based pharmaceutical companies, specializes in prescription pharmaceuticals, particularly biotechnology products.

Since the start of its strategic alliance with Roche in October 2002, Tokyo-based Chugai has been actively involved in prescription pharmaceutical R&D activities in Japan and abroad as an important member of the Roche Group. Specifically, Chugai offers products that significantly contribute to the improvement of treatments, leverage cutting-edge technologies in the fields of cancer, rheumatoid arthritis, renal anemia and hepatitis C.

In Japan, Chugai’s research facilities in Gotemba and Kamakura are working together to develop new pharmaceuticals, and technological research for industrial production is underway at the Ukima facility.

Overseas, Chugai Pharma USA and Chugai Pharma Europe, both subsidiaries of Chugai, are engaged in clinical development activities in the United States and Europe respectively.

The consolidated sales of Chugai in 2008 totaled 326.9 billion yen and the operating profit was 51.6 billion yen. Chugai targets to raise its consolidated sales to 460 billion yen and operating profit to 80 billion yen by 2012, as stated in its new mid-term business plan "Sunrise 2012."

Additional information is available on the Internet at http://www.chugai-pharm.co.jp/.